Drug Development & Delivery: INTRATUMORAL DELIVERY Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery?
INTRATUMORAL DELIVERY – Combining Local & Systemic Treatments: Could Immuno-Oncology Finally Enable Local Intratumoral Delivery?
Intensity Therapeutics’ Abstract (#3016) Selected for Oral Presentation as Part of a Poster Discussion Session at ASCO 2020
Intensity Therapeutics, Inc., a clinical-stage biotechnology company pioneering a novel, immune-based drug approach to treat solid tumor cancers through direct tumor injection, today announced that data highlighting the safety and efficacy results from the Company’s clinical trial of lead product candidate, INT230-6 dose alone and in combination with pembrolizumab, will be presented at the American… Read more »
Intensity Therapeutics Signs Clinical Collaboration Agreement with Bristol Myers Squibb for Advanced Solid Tumors
Intensity Therapeutics today announced it has entered into a clinical trial collaboration agreement with Bristol Myers Squibb Company (NYSE: BMY). The program will evaluate the safety and efficacy of Intensity’s lead product INT230-6, an investigational, novel and potent anti-cancer drug designed to directly kill cancer cells through intratumoral injection and improve immune cell recognition of… Read more »
Intensity Therapeutics Reports Safety Results from First Cohort of the KEYNOTE A10 Combination Clinical Trial of INT230-6 and Keytruda®
Intensity Therapeutics, Inc., a clinical-stage biotechnology company developing proprietary technology and products to kill tumors and increase immune system recognition, today announced successful completion of the safety lead in portion of the IT-01 KEYNOTE A10 study arm (NCT03058289) that is testing the combination of INT230-6, the Company’s lead investigational product, and Keytruda® (pembrolizumab), Merck’s anti-PD-1… Read more »
Presentation made November 9, 2019 by Dr. Jacob Thomas, Assistant Professor of Medicine University of Southern California.
OncoImmunology July 16, 2019 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory
Article published on-line July 16, 2019 in the journal OncoImmunology. https://doi.org/10.1080/2162402X.2019.1625687 Intratumorally delivered formulation, INT230-6, containing potent anticancer agents induces protective T cell immunity and memory. ABSTRACT The benefits of anti-cancer agents extend beyond direct tumor killing. One aspect of cell death is the potential to release antigens that initiate adaptive immune responses. Here, a… Read more »